Skip to main content
Division of Gastroenterology & Hepatology Gastroenterology & Hepatology
  1. HOME
  2. Research
  3. MASLD
  4. Research
  5. Publications

Publications

Recent Publications

  1. Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018. J Gen Intern Med. 2022 Jan;37(1):261-263.
  2. Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022 Jan;18(1):55-66.
  3. Byra M, Han A, Boehringer AS, Zhang YN, O'Brien WD Jr, Erdman JW Jr, Loomba R, Sirlin CB, Andre M. Liver Fat Assessment in Multiview Sonography Using Transfer Learning With Convolutional Neural Networks. J Ultrasound Med. 2022 Jan;41(1):175-184.
  4. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78.
  5. Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol. 2022 Jan 6:S1542-3565(22)00002-7.
  6. Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Enomoto N, Izumi N. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther. 2022 Feb;55(3):292-301.
  7. Chung SM, Kang MK, Jung J, Yoon JS, Won KC, Lee HW, Loomba R, Park JG, Moon JS. Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study. Diabetes Res Clin Pract. 2022 Feb;184:109208
  8. Natarajan Y, Loomba R. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):174-179.
  9. Qin Y, Havulinna AS, Liu Y, Jousilahti P, Ritchie SC, Tokolyi A, Sanders JG, Valsta L, Brożyńska M, Zhu Q, Tripathi A, Vázquez-Baeza Y, Loomba R, Cheng S, Jain M, Niiranen T, Lahti L, Knight R, Salomaa V, Inouye M, Méric G. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat Genet. 2022 Feb;54(2):134-142.
  10. Tamaki N, Imajo K, Sharpton SR, Jung J, Sutter N, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Kurosaki M, Izumi N, Nakajima A, Loomba R. Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2022 Feb 2 [Epub ahead of print]
  11. Tan DJH, Lim WH, Yong JN, Ng CH, Muthiah MD, Tan EX, Xiao J, Lim SY, Pin Tang AS, Pan XH, Kabir T, Bonney GK, Sundar R, Syn N, Kim BK, Dan YY, Noureddin M, Loomba R, Huang DQ. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clin Gastroenterol Hepatol. 2022 Feb 16:S1542-3565(22)00144-6.
  12. Lake JE, Overton T, Naggie S, Sulkowski M, Loomba R, Kleiner DE, Price JC, Chew KW, Chung RT, Corey KE. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clin Gastroenterol Hepatol. 2022 Feb;20(2):256-268.
  13. Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology. 2022 Mar;75(3):661-672.
  14. Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 Mar;76(3):536-548.
  15. Loomba R, Ratziu V, Harrison SA; NASH Clinical Trial Design International Working Group. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. Gastroenterology. 2022 Mar;162(3):680-688.
  16. Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatol Commun. 2022 Mar;6(3):461-472.
  17. Sanyal AJ, Shankar SS, Calle RA, Samir AE, Sirlin CB, Sherlock SP, Loomba R, Fowler KJ, Dehn CA, Heymann H, Kamphaus TN. Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nat Med. 2022 Mar;28(3):430-432.
  18. Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology. 2022 Mar 25.
  19. Zhang YN, Fowler KJ, Boehringer AS, Montes V, Schlein AN, Covarrubias Y, Wolfson T, Hong CW, Valasek MA, Andre MP, Loomba R, Sirlin CB. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. Eur Radiol. 2022 Apr;32(4):2457-2469.
  20. Danis N, Weeks SR, Kim A, Baghdadi A, Ghadimi M, Kamel IR, Saberi B, Woreta T, Garonzik-Wang J, Philosophe B, Gurakar A, Loomba R. Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm. Liver Transpl. 2022 Apr;28(4):670-677.
  21. Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022 Apr;55(8):894-907.
  22. Ajmera V, Nguyen K, Tamaki N, Sharpton S, Bettencourt R, Loomba R. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2022 Apr 29;15:17562848221093869.
  23. Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, Mae Diehl A, Abdelmalek MF, Chalasani N, Gawrieh S, Dasarathy S, Vuppalanchi R, Siddiqui MS, Kowdley KV, McCullough A, Terrault NA, Behling C, Kleiner DE, Fishbein M, Hertel P, Wilson LA, Mitchell EP, Miriel LA, Clark JM, Tonascia J, Sanyal AJ; NASH Clinical Research Network. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS One. 2022 Apr 15;17(4):e0266859.
  24. Fazeli S, Covarrubias Y, Bassirian S, Cuevas J, Fowler K, Vodkin I, Kono Y, Marks R, Loomba R, Taouli B, Sirlin C, Carlos R. Eliciting Patient Preferences for Hepatocellular Carcinoma Screening: A Choice-Based Conjoint Analysis. J Am Coll Radiol. 2022 Apr;19(4):502-512.
  25. Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, Mae Diehl A, Abdelmalek MF, Chalasani N, Gawrieh S, Dasarathy S, Vuppalanchi R, Siddiqui MS, Kowdley KV, McCullough A, Terrault NA, Behling C, Kleiner DE, Fishbein M, Hertel P, Wilson LA, Mitchell EP, Miriel LA, Clark JM, Tonascia J, Sanyal AJ; NASH Clinical Research Network. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS One. 2022 Apr 15;17(4):e0266859.
  26. Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022 Apr;23(4):521-530.
  27. Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther. 2022 Apr;55(7):820-827.
  28. Liu Y, Méric G, Havulinna AS, Teo SM, Åberg F, Ruuskanen M, Sanders J, Zhu Q, Tripathi A, Verspoor K, Cheng S, Jain M, Jousilahti P, Vázquez-Baeza Y, Loomba R, Lahti L, Niiranen T, Salomaa V, Knight R, Inouye M. Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. Cell Metab. 2022 May 3;34(5):719-730.e4.
  29. Sinakos E, Liava C, Loomba R. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. Ann Gastroenterol. 2022 May-Jun;35(3):213-225. Epub 2022 Apr 7.
  30. Rieman-Klingler, M. C., Jung, J., Tesfai, K. N., Loomba, R., & Non, A. L. (2022, April). Socioeconomic conditions, and not genetics alone, explain progression of nonalcoholic fatty liver disease. In AMERICAN JOURNAL OF BIOLOGICAL ANTHROPOLOGY (Vol. 177, pp. 152-153). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
  31. Tang A, Dzyubak B, Yin M, Schlein A, Henderson WC, Hooker JC, Delgado TI, Middleton MS, Zheng L, Wolfson T, Gamst A, Loomba R, Ehman RL, Sirlin CB. MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T. Eur Radiol. 2022 May;32(5):2937-2948.
  32. Ng CH, Lim WH, Hui Lim GE, Hao Tan DJ, Syn N, Muthiah MD, Huang DQ, Loomba R. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 May 2:S1542-3565(22)00439-6. Epub ahead of print.
  33. Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Aliment Pharmacol Ther. 2022 May;55(9):1076-1087
  34. Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther. 2022 May;55(9):1099-1115.
  35. Sharpton SR, Podlaha O, Chuang JC, Gindin Y, Myers RP , Loomba R. Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2022 May 18;15:17562848221098243.
  36. Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N; MRCH Liver Study Group. Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022 May;20(5):1171-1173.e2.
  37. Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB, Loomba R. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2022 May;71(5):983-990.
  38. Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJ, Loomba R, Noureddin M, Muthiah MD. Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology. 2022 Jun;75(6):1647-1661.
  39. Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatol Res. 2022 Jun;52(6):497-507.
  40. Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, Tamaki N, Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis. JAMA Netw Open. 2022 Jun 1;5(6):e2219407.
  41. Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022 Jul 5;34(7):969-977.e2.2022.05.003. Epub 2022 Jun 3.
  42. Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, Jia W, Panagiotou G. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med. 2022 Jun 8;14(648):eabk0855. Epub 2022 Jun 8.
  43. Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Current therapies and new developments in NASH. Gut. 2022 Jun 16:gutjnl-2021-326874. Epub ahead of print.
  44. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol. 2022 Jun;76(6):1362-1378.
  45. Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). Aliment Pharmacol Ther. 2022 Jun;55(11):1441-1451.
  46. Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Quach NE, Tu X, Zhang X, Noureddin M, Allen AM, Loomba R. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology. 2022 Jul 1:S0016-5085(22)00735-1. Epub ahead of print.
  47. Jung J, Han A, Madamba E, Bettencourt R, Loomba RR, Boehringer AS, Andre MP, Erdman JW Jr, O'Brien WD Jr, Fowler KJ, Sirlin CB, Loomba R. Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. Radiology. 2022 Jul;304(1):75-82.
  48. Thrift AP, Nguyen TH, Pham C, Balakrishnan M, Kanwal F, Loomba R, Duong HT, Ramsey D, El-Serag HB. The prevalence and determinants of NAFLD and MAFLD and their severity in the VA primary care setting. Clin Gastroenterol Hepatol. 2022 Jul 7:S1542-3565(22)00603-6. doi: 10.1016/j.cgh.2022.05.046. Epub ahead of print. PMID: 35811043.
  49. Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, Rivas G, Hummer B, Kimball SR, Geyer NR, Chinchilli VM, Loomba R, Schmitz K, Sciamanna C. NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. Hepatology. 2022 Jul;76(1):172-185.
  50. Cunha GM, Delgado TI, Middleton MS, Liew S, Henderson WC, Batakis D, Wang K, Loomba R, Huss RS, Myers RP, Sirlin CB, Fowler KJ, Hasenstab KA. Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance. AJR Am J Roentgenol. 2022 Aug;219(2):224-232.
  51. Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, Dan YY, Roberts LR, Loomba R, Huang DQ. Global Burden of Liver Cancer in Males and Females: Changing Etiological Basis and the Growing Contribution of NASH. Hepatology. 2022 Aug 29.
  52. Huang D, Downes M, Evans R, Witztum J, Glass C, Loomba R. Shared mechanisms between cardiovascular disease and NAFLD. Semin Liver Dis. 2022 Aug 25. doi: 10.1055/a-1930-6658. Epub ahead of print. PMID: 36008083.
  53. Carvalho-Gontijo R, Han C, Zhang L, Zhang V, Hosseini M, Mekeel K, Schnabl B, Loomba R, Karin M, Brenner DA, Kisseleva T. Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD. Semin Liver Dis. 2022 Aug;42(3):233-249.
  54. Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD, Hamilton JC, San Martin J, Teckman JH. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514-524.
  55. Huang DQ, Tan DJH, Ng CH, Amangurbanova M, Sutter N, Lin Tay PW, Lim WH, Yong JN, Tang A, Syn N, Muthiah MD, Tan EXX, Dave S, Tay B, Majzoub AM, Gerberi D, Kim BK, Loomba R. Hepatocellular Carcinoma Incidence in Alcohol-associated Cirrhosis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Aug 5:S1542-3565(22)00727-3.
  56. Ng CH, Lim WH, Chin YH, Yong JN, Zeng RW, Chan KE, Tan DJH, Fu CE, Tang ASP, Goh LH, Devi K, Chew NWS, Mak LL, Tamaki N, Huang DQ, Noureddin M, Siddiqui MS, Loomba R, Sanyal AJ, Muthiah M. Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. Aliment Pharmacol Ther. 2022 Aug;56(4):570-579.
  57. Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Lin T, Tu XM, Bergstrom J, Nguyen K, Nguyen L, Le T, Madamba E, Richards L, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Head to head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol. 2022 Aug 13:S0168-8278(22)02984-1. doi: 10.1016/j.jhep.2022.07.020. Epub ahead of print. PMID: 35973577
  58. Zobair M. Younossi, Maria Stepanova, Fatema Nader, Rohit Loomba, Quentin M. Anstee, Vlad Ratziu, Stephen Harrison, Arun J. Sanyal, Jörn M. Schattenberg, A. Sidney Barritt, Mazen Noureddin, Martin Bonacci, Gail Cawkwell, Bruce Wong, Mary Rinella,. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis." Clinical Gastroenterology and Hepatology, vol. 20, no. 9, 2022, pp. 2050-2058.e12, https://doi.org/10.1016/j.cgh.2021.07.020.
  59. Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol. 2022 Sep;77(3):607-618.
  60. Chhatwal J, Dalgic OO, Chen W, Samur S, Bethea ED, Xiao J, Hur C, Corey KE, Loomba R. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2022 Sep 1;5(9):e2230426.
  61. Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R; NAFLD Research Study Group. Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022 Sep 5:S1542-3565(22)00832-1. Online ahead of print
  62. Loomba R, Huang DQ, Sanyal AJ, et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. Published Online First: 09 September 2022.
  63. Lazarus JV, Castera L, Mark HE, Allen AM, Adams LA, Anstee QM, Arrese M, Alqahtani SA, Bugianesi E, Colombo M, Cusi K, Hagström H, Loomba R, Romero-Gómez M, Schattenberg JM, Thiele M, Valenti L, Wai-Sun Wong V, Yilmaz Y, Younossi ZM, Francque S, Tsochatzis EA. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. JHEP Reports. 2022 Sep 22.
  64. Sharpton SR, Oh TG, Madamba E, Wang C, Yu RT, Atkins AR, Huan T, Downes M, Evans MR, Loomba R. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. Aliment Pharmacol Ther. 2022 Sep 26.
  65. Lin Tay PW, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Hao Tan DJ, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants. Am J Gastroenterol. 2022 Sep 30 Epub ahead of print. PMID: 36191268.
  66. Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2022 Oct 18:1-13. Epub ahead of print. PMID: 36258033; PMCID: PMC9579565.
  67. Tan DJH, Quek SXZ, Yong JN, Suresh A, Koh KXM, Lim WH, Quek J, Tang A, Tan C, Nah B, Tan E, Keitoku T, Muthiah MD, Syn N, Ng CH, Kim BK, Tamaki N, Ho CSH, Loomba R, Huang DQ. Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis. Clin Mol Hepatol. 2022 Oct;28(4):864-875. Epub 2022 Jul 25. PMID: 36263668; PMCID: PMC9597225.
  68. Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, Kono Y, Dave S, Ahmed A, Sundaram V, Wilkinson MJ, Patton H, Gupta H, Cervantes V, Hernandez C, Lopez SJ, Loomba R, Baumgartner A, Richards L, Arkkila PE, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest. 2022 Nov 1;132(21):e162513. PMID: 36317632; PMCID: PMC9621132.
  69. Nedrud MA, Chaudhry M, Middleton MS, Moylan CA, Lerebours R, Luo S, Farjat A, Guy C, Loomba R, Abdelmalek MF, Sirlin CB, Bashir MR. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. Radiology. 2022 Nov 1:220743. Epub ahead of print. PMID: 36318027.
  70. Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, Fowler KJ, Alazraki A, Trout AT, Ohliger MA, Shah SN, Bashir M, Kleiner DE, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Zhou J, Sirlin CB, Lavine JE, Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. Journal of hepatology. 2022 Nov 8.
  71. Amangurbanova M, Huang DQ, Loomba R. The role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Alimentary Pharmacology & Therapeutics. 2022 Nov 9.
  72. Vilar-Gomez E, Liang T, Yates K, Wilson L, Loomba R, Chalasani N. The protection conferred by HSD17B13 rs72613567 on hepatic fibrosis is likely mediated by lowering ballooning and portal inflammation. Clinical Gastroenterology and Hepatology. 2022 Nov 17.
  73. Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. Journal of Hepatology. 2022 Nov 19.
  74. Xiao J, Ng CH, Chan KE, Fu C, Tay P, Yong JN, Lim WH, Tan DJ, Syn N, Wong ZY, Tseng M, Chew N, Huang DQ, Dan YY, Wong VW, Loomba R, Siddiqui MS, Sanyal AJ, Noureddin M, Muthiah MD. Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD. An Umbrella Overview of Systematic Review of Meta-Analysis. Journal of Clinical and Experimental Hepatology. 2022 Nov 19.
  75. Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Lin T, Tu XM, Bergstrom J, Nguyen K, Nguyen L, Nguyen L, Le T, Madamba E, Richards L, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba A. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. Journal of Hepatology. 2022 Dec 1;77(6):1482-90.
More...

Editorials

  1. Stinton L*, Loomba R. Dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet. Aliment Pharmacol Ther. 2014 Apr;39(8):894-5
  2. Loomba R. Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis . Clin Gastroenterol Hepatol. 2014 Oct;12(10):1731-2
  3. Loomba R. Rationale for conducting randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: Pleiotropic effects hypothesis. Hepatology 2014 Dec;60(6):1818- 22
  4. Roh YS, Loomba R, Seki E. The TM6SF2 Variants, Novel Genetic Predictors for Nonalcoholic Steatohepatitis. Gastroenterology 2015 Jan;148(1):252-4
  5. Spengler EKJ*, Loomba R. Gut microbiome, Intestinal permeability, bacterial translocation and NAFLD. Cellular and Molecular Gastroenterology and Hepatology 2015 Mar; 1 (2);129-130
  6. Verna EC, Loomba R. Call to screen for NAFLD and NASH in psoriasis. Aliment Pharmacol Ther. 2015 Mar;41(5):492-3
  7. Loomba R, Cortez-Pinto H. Exercise and improvement of NAFLD: Practical recommendations. J Hepatol. 2015 Jul;63(1):10-2.
  8. Konerman M, Loomba R. Diabetes and its association with hepatocellular carcinoma in chronic hepatitis B . Aliment Pharmacol Ther. 2015 Jul;42(1):117-8
  9. Loomba R, Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. Gastroenterology. 2015 Aug;149(2):278-81
  10. Singh S and Loomba R. Obesity in chronic liver diseases - increased infections. Aliment Pharmacol Ther. 2016 Jan;43(2):311-2
  11. Kishore R, Loomba R, Sterling RK. Editorial: A New Spin on Magnetic Resonance Elastography. Am J Gastroenterol. 2016 Jun;111(6):834-7
  12. Konerman MA, Loomba R. Editorial: the burden and aetiology of liver cirrhosis, and the risk of death. Aliment Pharmacol Ther. 2016 Jul;44(2):202-3
  13. Malhi H, Loomba R. Editorial: dark chocolate may improve NAFLD and metabolic syndrome by reducing oxidative stress. Aliment Pharmacol Ther. 2016 Sep;44(5):533-4
  14. Venkatesh SK, Loomba R. Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging. J Hepatol. 2016 Dec;65(6):1079-1080.
  15. Ajmera V, Loomba R. Editorial: non-alcoholic fatty liver disease-a pandemic in need of novel treatments and endpoints. Aliment Pharmacol Ther. 2017 Jul;46(1):65-66
  16. Singh S, Loomba R. Role of 2D Shear Wave Elastography in the Assessment Of Chronic Liver Diseases. Hepatology. 2018 Jan;67(1):13-15
  17. Ajmera V , Loomba R. Do Zones of Hepatic Steatosis Associate With Subtypes and Progression of Nonalcoholic Fatty Liver Disease in Children? Clin Gastroenterol Hepatol. 2018 Mar;16(3):341-342
  18. Tapper EB, Loomba R. NAFLD, Metabolic Syndrome, and the Fight That Will Define Clinical Practice for a Generation of Hepatologists. Hepatology. 2018 May;67(5):1657-1659
  19. Noureddin M, Loomba R. Editorial: role of leucine-metformin-sildenafil combination in the
    treatment of nonalcoholic fatty liver disease (NAFLD). Aliment Pharmacol Ther. 2018 Aug;48(3):378-379
  20. Ajmera V, Loomba R. Refining Sample-Size Estimations Based Upon Placebo Response in Trials of Agents for Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019 Mar;17(4):607-609
  21. Schattenberg JM, Loomba R. Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis . Hepatology. 2019 Mar;69(3):934-936 .
  22. Mehal WZ, Loomba R. The Intestinal Microbiome, Plasma Metabolome and Liver Transcriptome- A Conspiracy Driving Hepatic Steatosis. Hepatology. 2019 Aug;70(2):741-744
  23. Balakrishnan M, Loomba R. PROs of Patient-reported Outcomes for Nonalcoholic Fatty Liver Disease and Effects on Treatment for Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2019 Sep;17(10):1950-1953
  24. Loomba R, Adams LA. The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH. Hepatology. 2019 Dec;70(6):1885-1888.
  25. Stender S, Loomba R. PNPLA3 genotype and risk of liver and all-cause mortality. Hepatology. 2020 Mar;71(3):777-779.
  26. Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, Gordon SC. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply. Aliment Pharmacol Ther. 2020 Jun;51(11):1200-1201.
  27. Vuppalanchi R, Loomba R. Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box. Hepatology. 2021 Jun;73(6):2095-2098.
  28. Huang DQ, Loomba R. Editorial: screening for hepatocellular carcinoma in NAFLD. Alimentary Pharmacology & Therapeutics, 55(9).
  29. Flint A, Andersen G, Hockings P, Plum-Mörschel L, Loomba R. Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity - authors' reply. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1498.
  30. Brubaker AL, Loomba R. Utilizing Macrosteatotic Allografts for Nonalcoholic Steatohepatitis Recipients. Liver Transpl. 2022 Apr;28(4):552-553.
  31. Huang DQ, Loomba R. Editorial: screening for hepatocellular carcinoma in NAFLD cirrhosis-towards abbreviated MRI alternative in patients with obesity? Authors' reply. Aliment Pharmacol Ther. 2022 May;55(9):1212-1213.